U.S. markets closed

Rigel Pharmaceuticals, Inc. (RIGL)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
1.4800-0.0100 (-0.67%)
Al cierre: 04:00PM EDT
1.4711 -0.01 (-0.60%)
Fuera de horario: 07:01PM EDT

Rigel Pharmaceuticals, Inc.

611 Gateway Blvd
Suite 900
South San Francisco, CA 94080
United States
650 624 1100
https://www.rigel.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo147

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Raul R. RodriguezPresident, CEO & Director1.09MN/D1961
Mr. Dean L. Schorno CPAExecutive VP & CFO696.67kN/D1963
Mr. Raymond J. Furey J.D.Executive VP, General Counsel & Corporate Secretary593.46kN/D1968
Mr. David A. SantosExecutive VP & Chief Commercial Officer681.63kN/D1963
Ms. Julie PatelSenior VP of Human ResourcesN/DN/DN/D
Dr. Esteban S. MasudaExecutive Vice President of Research537.21kN/D1962
Mr. Joseph LasagaExecutive VP & Chief Business OfficerN/DN/D1975
Dr. Lisa Rojkjaer M.D.Executive VP & Chief Medical OfficerN/DN/D1966
Mr. Tarek SallamVice President of MarketingN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Gestión corporativa

La calificación ISS Governance QuickScore de Rigel Pharmaceuticals, Inc. a partir del 1 de marzo de 2024 es 4. Las puntuaciones principales son Auditoría: 7; Junta: 4; Derechos del accionista: 3; Compensación: 6.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.